Scholarlink

<p>To evaluate the clinical course of patients with AF at high risk for both bleeding and stroke, according to OAC use. Data were analysed from three registries across the Middle East, Europe, and Asia-Pacific regions. The study only included ‘high risk’ patients with AF and CHA₂DS₂-VASc scores ≥ 2 and HAS-BLED scores ≥ 3, who were divided into two groups based on OAC use: OAC <i>users</i> and OAC <i>non-users</i>. Of the 2,535 patients (41.7% female; mean age 75.4 ± 7.8 years), 80.3% (<i>n</i> = 2,037) received OAC therapy. OAC <i>non‑users</i> showed significantly higher crude 1‑year event rates of all‑cause death (116 [23.3%]), MACE (96 [19.3%]) and major bleeding (31 [6.2%]); after multivariable adjustment, they had higher odds of all‑cause death (adjusted odds ratio (aOR) 2.23, 95% CI 1.65–3.01), MACE (aOR 1.92, 95% CI 1.38–2.64) and major bleeding (aOR 2.38, 95% CI 1.42–3.92) compared to OAC <i>users</i>. Enrolment in a non-European setting was associated with a lower risk of all-cause death (aOR 0.61, 95%CI 0.44–0.85) and MACE (aOR 0.42, 95%CI 0.28–0.62). In patients with AF at high risk of both bleeding and stroke, OAC <i>non-use</i> was associated with higher risk of adverse events and bleeding. Decisions on discontinuation of OACs in this subset of patients with AF should be cautiously made and such patients require careful re-evaluation and follow-up.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-world outcomes of oral anticoagulation in patients with atrial fibrillation at high risk of both bleeding and stroke: observational evidence from three international registries from middle East, Europe and Asia-Pacific

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月22日

查看全文
  • Amir Askarinejad,
  • Tommaso Bucci,
  • Enrico Tartaglia,
  • Steven H. M. Lam,
  • Michele Rossi,
  • Manlin Zhao,
  • Hung-Fat Tse,
  • Majid Haghjoo,
  • Giuseppe Boriani,
  • Tze-Fan Chao,
  • Gregory Y. H. Lip

摘要

To evaluate the clinical course of patients with AF at high risk for both bleeding and stroke, according to OAC use. Data were analysed from three registries across the Middle East, Europe, and Asia-Pacific regions. The study only included ‘high risk’ patients with AF and CHA₂DS₂-VASc scores ≥ 2 and HAS-BLED scores ≥ 3, who were divided into two groups based on OAC use: OAC users and OAC non-users. Of the 2,535 patients (41.7% female; mean age 75.4 ± 7.8 years), 80.3% (n = 2,037) received OAC therapy. OAC non‑users showed significantly higher crude 1‑year event rates of all‑cause death (116 [23.3%]), MACE (96 [19.3%]) and major bleeding (31 [6.2%]); after multivariable adjustment, they had higher odds of all‑cause death (adjusted odds ratio (aOR) 2.23, 95% CI 1.65–3.01), MACE (aOR 1.92, 95% CI 1.38–2.64) and major bleeding (aOR 2.38, 95% CI 1.42–3.92) compared to OAC users. Enrolment in a non-European setting was associated with a lower risk of all-cause death (aOR 0.61, 95%CI 0.44–0.85) and MACE (aOR 0.42, 95%CI 0.28–0.62). In patients with AF at high risk of both bleeding and stroke, OAC non-use was associated with higher risk of adverse events and bleeding. Decisions on discontinuation of OACs in this subset of patients with AF should be cautiously made and such patients require careful re-evaluation and follow-up.

Graphical abstract